Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in this setting. To evaluate the utility of the hypoxia-activated prodrug evofosfamide (TH-302) in HNSCC, we established t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Julia K. Harms, Tet-Woo Lee, Tao Wang, Amy Lai, Dennis Kee, John M. Chaplin, Nick P. McIvor, Francis W. Hunter, Andrew M. J. Macann, William R. Wilson, Stephen M.F. Jamieson
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2019-07-01
coleção:	Cells
Assuntos:	tumour hypoxia head and neck squamous cell carcinoma (HNSCC) evofosfamide patient-derived xenograft (PDX) pimonidazole POR MKI67 SLFN11
Acesso em linha:	https://www.mdpi.com/2073-4409/8/7/717
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!